An Unusual Skin Adverse Event after Switching from Intravenous to Subcutaneous VEDOLIZUMAB Therapy in Patients with Ulcerative Colitis. acmcr. 2023;7(1):77-79. Accessed September 11, 2026. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22706